Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H36F2O6 |
| Molecular Weight | 482.5572 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)COC3=C(F)C=CC(F)=C3)[C@@]1([H])CC[C@H](CCCC(=O)OC(C)C)CO2
InChI
InChIKey=BKVUSNOUTQMSBE-XCMGCKIWSA-N
InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1
Sepetoprost (also known as ONO-9054), prostaglandin analog was developed as a dual agonist of prostaglandin E3 (EP3) and prostaglandin F (FP) receptors. It is known, that the use of a dual prostaglandin EP3 and prostaglandin F receptor agonists is a novel approach for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Sepetoprost was successfully studied in clinical trials phase II for the treatment of open-angle glaucoma, ocular hypertension, and mild open angle-glaucoma.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. | 2015 Dec |
|
| Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study. | 2016 Oct |
|
| Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. | 2019 Apr |
Patents
Sample Use Guides
Nine subjects were randomized to each of ONO-9054 (sepetaprost) 3, 10, 20, 30 μg/mL and 12 to placebo. Subjects received a single drop to each eye at 07:00±30 minutes (single dose). Following a 4-day no-treatment period, subjects were dosed once daily for 14 consecutive days (multiple day dosing)
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SEPETAPROST
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 ?g/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days. | ||
|
300000031915
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
79O7855J4G
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
9850
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
C152337
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
50902259
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
1262873-06-2
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY | |||
|
DB12043
Created by
admin on Sat Dec 16 09:47:05 GMT 2023 , Edited by admin on Sat Dec 16 09:47:05 GMT 2023
|
PRIMARY |
METABOLITE ACTIVE (PRODRUG)
SUBSTANCE RECORD
